enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Growth Opportunities F. Forbion Buys 10,020 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion bought 10,020 shares of the firm’s stock in a transaction dated Friday, December 29th. The stock was acquired at an average cost of $9.06 per share, with a total value of $90,781.20. Following the transaction, the insider now owns 2,017,820 shares of the company’s stock, valued at $18,281,449.20. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

enGene Stock Down 3.0 %

ENGN opened at $9.02 on Friday. The company has a market capitalization of $398.38 million, a PE ratio of -5.24 and a beta of -0.69. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. enGene Holdings Inc. has a fifty-two week low of $4.42 and a fifty-two week high of $43.00. The business has a 50-day moving average of $6.71 and a 200-day moving average of $9.78.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.05. Equities research analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On enGene

Institutional investors and hedge funds have recently modified their holdings of the business. Logos Global Management LP increased its position in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the last quarter. SR One Capital Management LP bought a new stake in shares of enGene during the 2nd quarter worth about $4,715,000. Janus Henderson Group PLC acquired a new position in shares of enGene during the 1st quarter valued at about $17,095,000. Finally, Altitude Crest Partners Inc. bought a new position in shares of enGene in the 1st quarter valued at approximately $2,039,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Morgan Stanley restated an “overweight” rating and set a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene presently has a consensus rating of “Buy” and a consensus target price of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.